Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNCT-VERGE Phase 3 Study in Recurrent IDH-wildtype Glioblastoma
jRCT2051260030Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of borofalan in glioblastoma (GBM) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Overall Survival. Started May 2026; status: recruiting.
02
Drugs
borofalan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2051260030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260030.